While recent draft guidance from the Food and Drug Administration on artificial intelligence-enabled medical devices is non-binding, the document signals that the agency is intensifying its regulatory scrutiny of these technologies, said Dr. Scott Schell of IT consulting firm Cognizant.
First seen on govinfosecurity.com
Jump to article: www.govinfosecurity.com/interviews/reading-tea-leaves-in-fdas-ai-enabled-device-guidelines-i-5468
